Radiation Safety Survey

This survey is confidential and anonymous. It will take only a few minutes to complete.

Here is the survey link

The objective of this survey is to evaluate whether there has been a change in practice regarding the release of patients after they receive radioactive iodine (RAI or I-131) for treatment of differentiated thyroid cancer (papillary, follicular, or their variants).  

In 2011 the U.S. Nuclear Regulatory Commission issued a RIS publication that strongly discouraged patients from residing in locations other than a private residence after receiving RAI. 

This survey study is being conducted by Douglas Van Nostrand, M.D., ThyCa Medical Advisor, and colleagues.